argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
788.49
-7.08 (-0.89%)
At close: Jan 9, 2026, 4:00 PM EST
790.00
+1.51 (0.19%)
After-hours: Jan 9, 2026, 5:42 PM EST
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.69B, up 93.18% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.52% growth.
Revenue (ttm)
$3.69B
Revenue Growth
+93.18%
P/S Ratio
13.41
Revenue / Employee
$2,303,490
Employees
1,599
Market Cap
49.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARGX News
- 3 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
- 4 days ago - argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 days ago - argenx Announces Leadership Transition Marking Next Evolution of Growth - GlobeNewsWire
- 18 days ago - 5 Top Stocks With High 2026 Earnings Growth Targets - Seeking Alpha
- 24 days ago - Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update - Seeking Alpha
- 25 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 25 days ago - Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 26 days ago - argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease - GlobeNewsWire